Oncology Prostate and Urologic Cancers Prostate Metastatic Hormone Sensitive
Categories
Protocols
HCRN-GU19-385-PLANE-PC Phase II OPEN TO ACCRUAL
Phase II trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer